Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DM95PZ
|
|||
| Drug Name |
ID1201
|
|||
| Indication | Alzheimer disease [ICD-11: 8A20; ICD-10: G30, G30.9; ICD-9: 331] | Phase 2 | [1] | |
| Company |
IlDong Pharmaceutical
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Alpha-secretase (ASE) | Target Info | Enhancer | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03363269) A Multi-center, Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Evaluate the Efficacy and Safety of ID1201 for Dose-finding in Mild Alzheimer's Disease. U.S.National Institutes of Health. | |||
| REF 2 | Anti-amyloidogenic effects of ID1201, the ethanolic extract of the fruits of Melia toosendan, through activation of the phosphatidylinositol 3-kinase/Akt pathway. Environ Toxicol Pharmacol. 2014 Mar;37(2):513-20. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.